Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 59

TitleReference numberPublishedLast updated
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancerTA876
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiationTA798
Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterationsTA789
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancerTA781
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resectionTA761
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancerTA760
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancerTA724
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapyTA713
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643

Results per page

  1. 10
  2. 25
  3. 50
  4. All